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Short- and long-term exposure to air pollution
has been associated with increased cardio-
vascular mortality and morbidity (Pope et al.
2002; Samet et al. 2000; Schwartz 1999), and
individuals with underlying cardiovascular dis-
ease, including heart failure, arrhythmia, or dia-
betes, are at greater risk (Bateson and Schwartz
2004; Goldberg et al. 2001; Mann et al. 2002;
Zanobetti and Schwartz 2002). Possible mech-
anisms for these associations include effects on
the autonomic nervous system through direct
reﬂexes from airways or through inﬂammatory
response, chemical effects on ion channel func-
tion in myocardial cells, ischemic response in
the myocardium, and inﬂammatory responses
that trigger endothelial dysfunction, athero-
sclerosis, and thrombosis (Utell et al. 2002).
Heart rate variability (HRV) is a widely
used noninvasive and quantitative marker of
cardiac autonomic control. HRV reﬂects auto-
nomic modulation of the rhythmic activity of
the sinus node and is analyzed in the time
or frequency domains (Task Force 1996).
Sustained reductions of HRV have been asso-
ciated with increased risk of mortality in mid-
dle-age and elderly subjects, in patients with
diabetes, and in survivors of myocardial infarc-
tion and other cardiovascular diseases (Dekker
et al. 1997; Gerritsen et al. 2001; Tapanainen
et al. 2002; Tsuji et al. 1996). Air pollution,
especially particulate matter < 2.5 µm in aero-
dynamic diameter (PM2.5), has been associated
with alterations in HRV (Creason et al. 2001;
Devlin et al. 2003; Gold et al. 2000; Holguin
et al. 2003; Liao et al. 1999, 2004; Magari
et al. 2001, 2002; Pope et al. 1999, 2004).
However, only two studies explored whether
clinical conditions or other subject characteris-
tics modiﬁed the association between air pollu-
tion and HRV (Holguin et al. 2003; Liao et al.
2004). Little has been reported to date on asso-
ciations with particle components.
In this study we examine the relationship
between alterations in HRV and ambient air
pollutants among community residents. We
also investigated modifying effects of hyperten-
sion, ischemic heart disease (IHD), diabetes,
and use of commonly prescribed antihyperten-
sive medications that increase cardiac vagal
activity (Lampert et al. 2003; Tomiyama et al.
1998; Townend et al. 1995).
Materials and Methods
Study population. The Normative Aging Study
is a longitudinal study of aging established
by the Veterans Administration in 1963, when
2,280 men from the Greater Boston area
(21–81 years of age) confirmed to be free
of known chronic medical conditions were
enrolled (Bell et al. 1972). Participants were
asked to return for examinations every
3–5 years. Among active cohort members,
603 persons were examined from 14 November
2000 through 30 October 2003.
Participants visited the study center in
the morning, after an overnight fast and absti-
nence from smoking. Weight and height were
measured to compute body mass index (BMI).
With the subject seated, heart rate and systolic
and diastolic blood pressures were measured by
a physician. The mean of the left and right
arm measurements was used. For this study,
we defined mean arterial blood pressure
(MAP) as diastolic pressure plus one-third of
the difference between systolic and diastolic
blood pressure. Subjects with diabetes were
defined by a physician’s diagnosis of type 2
diabetes and/or use of a diabetes medication
(e.g., oral hypoglycemic drug, metformin, or
insulin). Hypertension was deﬁned as systolic
blood pressure of ≥ 140 mm Hg, diastolic
blood pressure of ≥ 90 mm Hg, or reported
use of hypertension medication. Cigarette
smoking, alcohol consumption, and subjects’
use of medications were assessed by question-
naire. Medication use was confirmed by a
physician interview. Prevalent IHD was identi-
ﬁed using the Framingham Heart Study crite-
ria for myocardial infarction and angina
pectoris (Shurtleff 1974). Temperature of the
room where the electrocardiogram (ECG) was
taken was recorded.
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Reduced heart rate variability (HRV), a marker of poor cardiac autonomic function, has been
associated with air pollution, especially ﬁne particulate matter [< 2.5 µm in aerodynamic diameter
(PM2.5)]. We examined the relationship between HRV [standard deviation of normal-to-normal
intervals (SDNN), power in high frequency (HF) and low frequency (LF), and LF:HF ratio] and
ambient air pollutants in 497 men from the Normative Aging Study in greater Boston,
Massachusetts, seen between November 2000 and October 2003. We examined 4-hr, 24-hr, and
48-hr moving averages of air pollution (PM2.5, particle number concentration, black carbon,
ozone, nitrogen dioxide, sulfur dioxide, carbon monoxide). Controlling for potential confounders,
HF decreased 20.8% [95% confidence interval (CI), 4.6–34.2%] and LF:HF ratio increased
18.6% (95% CI, 4.1–35.2%) per SD (8 µg/m3) increase in 48-hr PM2.5. LF was reduced by
11.5% (95% CI, 0.4–21.3%) per SD (13 ppb) increment in 4-hr O3. The associations between
HRV and PM2.5 and O3 were stronger in people with ischemic heart disease (IHD) and hyper-
tension. The associations observed between SDNN and LF and PM2.5 were stronger in people
with diabetes. People using calcium-channel blockers and beta-blockers had lower associations
between O3 and PM2.5 with LF. No effect modiﬁcation by other cardiac medications was found.
Exposures to PM2.5 and O3 are associated with decreased HRV, and history of IHD, hyper-
tension, and diabetes may confer susceptibility to autonomic dysfunction by air pollution.
Key words: air pollution, diabetes, heart rate variability, hypertension, ischemic heart disease,
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http://dx.doi.org/ [Online 6 December 2004]HRV measurement. We measured HRV
between 0600 and 1300 hr using a two-
channel (five-lead) ECG monitor (Trillium
3000; Forest Medical, East Syracuse, NY). A
detailed description of the HRV measure-
ment protocol is provided elsewhere (Pope
et al. 2001). Brieﬂy, after the participants had
rested for 5 min, the ECG was recorded
(sampling rate of 256 Hz per channel) for
approximately 7 min with the subject seated.
We used the best 4-consecutive-minute inter-
val for the HRV calculations. The ECG digi-
tal recordings were processed, and heart rate
and HRV measures were calculated using
PC-based software (Trillium 3000 PC
Companion Software for MS Windows;
Forest Medical). Beats were automatically
detected and assigned tentative annotations,
which were then reviewed by an experienced
scanner to correct for any mislabeled beats or
artifacts. Only normal-to-normal (NN) beat
intervals were included in the analysis. We
computed standard deviation of NN intervals
(SDNN), the square root of the mean of the
squared differences between adjacent NN
intervals (r-MSSD), high-frequency power
(HF) (0.15–0.4 Hz), low-frequency power
(LF) (0.04–0.15 Hz), and LF:HF ratio.
Ninety-two subjects with problematic heart
rate measurements (atrial fibrillation, atrial
bigeminy and trigeminy, pacemakers, irregular
rhythm, irregular sinus rhythm, frequent ven-
tricular ectopic activity, ventricular bigeminy,
multifocal atrial tachycardia, or measurement
time < 3.5 min) were excluded.
Air pollution and weather data. Con-
tinuous PM2.5, particle number concentration
(PN), and black carbon (BC) were measured at
the Harvard School of Public Health monitor-
ing site, 1 km from the exam site, using a
Tapered Element Oscillating Microbalance
(TEOM) (model 1400A; Rupprecht &
Pataschnick Co., East Greenbush, NY), conden-
sation particle counter (model 3022A; TSI Inc.,
Shoreview, MN), and aethalometer (Magee
Scientiﬁc, Berkeley, CA), respectively. Because
the TEOM sample ﬁlter is heated to 50°C, a
season-speciﬁc correction was used to compen-
sate for the loss of semivolatile mass that occurs
at this temperature (Allen et al. 1997). Ozone,
sulfur dioxide, nitrogen dioxide, carbon mon-
oxide, temperature, and dew-point tempera-
ture measurements were obtained from the
Massachusetts Department of Environmental
Protection local monitoring sites. The gaseous
pollutants are measured hourly using U.S.
Environmental Protection Agency (EPA) refer-
ence methods (U.S. EPA 2002).
To control for weather, we used apparent
temperature, defined as a person’s perceived
air temperature (O’Neill et al. 2003). It was
calculated with the following formula: –2.653
+ (0.994 × air temperature) + (0.0153 × dew-
point temperature). We estimated missing
PM2.5, PN, and BC measures using a regres-
sion model with date, day of week, hour of
day, temperature, relative humidity, pressure,
and NO2 as predictors (6.4% missing for
PM2.5, 7.5% for PN, and 0.5% for BC). To
evaluate lagged effects of air pollutants, we
used 4-hr, 24-hr, and 48-hr moving averages
of air pollution matched on the time of meas-
uring ECG for each subject. These averaging
times were chosen based on previous reports
in the literature.
Statistical methods. Measures of HRV were
log10-transformed to improve normality and
stabilize the variance. Linear regression analyses
were carried out to evaluate the relation of
HRV with each air pollutant. Cardiac medica-
tions were categorized as beta-blocker, calcium-
channel blocker, and angiotensin-converting
enzyme (ACE) inhibitor. After 14 subjects
with missing values of the potential confound-
ing factors were excluded, 497 subjects with
complete data were available for the analyses.
The following variables were chosen a
priori as clinically important predictors and
included in the models: age, BMI, fasting
blood glucose (FBG), cigarette smoking, use
of cardiac medications, room temperature,
season, and the lagged moving average of
apparent temperature corresponding to the
same moving average period for each air
pollutant. MAP was also included because
this changed the estimated effect of some
air pollutants by more than 10%. To model
the nonlinear association of apparent temper-
ature with HRV, we used a cubic spline with
3 degrees of freedom (df).
We estimated the percent change in each
HRV parameter for 1 SD increase for each
pollutant as [10(β × SD) – 1] × 100%, with 95%
conﬁdence intervals (CI) {10[SD × (β ± 1.96 × SE)]
– 1} × 100%, where β and SE are the esti-
mated regression coefficient and its standard
error. To test whether observed associations
in single-pollutant models were robust to
inclusion of another pollutant, two-pollutant
models were fitted. To assess modifying
effects of hypertension, IHD, diabetes or use
of cardiac/antihypertensive medications, we
ran separate regressions stratified by those
variables and compared the percent changes
of each pollutant. We also ran regression
models including interaction terms.
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Table 1. Characteristics [mean ± SD or n (%)] of the study subjects.
Hypertension
Variable All subjects (n = 497) Without (n = 162) With (n = 335)
Age (years) 72.7 ± 6.6 71.2 ± 6.5 73.4 ± 6.5
BMI (kg/m2) 28.3 ± 4.1 27.2 ± 3.9 28.7 ± 4.1
Systolic blood pressure (mm Hg) 131.4 ± 16.3 125.0 ± 10.5 134.5 ± 17.7
Diastolic blood pressure (mm Hg) 75.7 ± 9.4 75.3 ± 7.1 75.9 ± 10.3
MAP (mm Hg) 94.3 ± 10.2 91.9 ± 7.2 95.5 ± 11.2
Heart rate (beat/min) 70.7 ± 6.7 71.4 ± 5.8 70.4 ± 7.1
Fasting blood glucose (mg/dL) 108.0 ± 29.0 103.1 ± 22.3 110.3 ± 31.5
Cholesterol (mg/dL) 197.0 ± 37.6 207.1 ± 36.2 192.1 ± 37.4
High-density lipoprotein (mg/dL) 49.7 ± 13.5 52.9 ± 15.3 48.1 ± 12.3
Triglycerides (mg/dL) 129.8 ± 71.5 122.0 ± 66.7 133.5 ± 73.5
Smoking status [n (%)]
Never smoker 160 (32.2) 58 (35.8) 102 (30.4)
Former smoker 311 (62.6) 93 (57.4) 218 (65.1)
Current smoker 26 (5.2) 11 (6.8) 15 (4.5)
Alcohol intake (≥ 2 drinks/day) [n (%)] 96 (19.3) 30 (18.5) 66 (19.7)
Diabetes mellitus [n (%)] 72 (14.5) 14 (8.6) 58 (17.3)
IHD history [n (%)] 142 (28.6) 16 (9.9) 126 (37.6)
Use of beta-blocker [n (%)] 163 (32.8) 0 (0.0) 163 (48.7)
Use of calcium-channel blocker [n (%)] 70 (14.1) 0 (0.0) 70 (20.9)
Use of ACE inhibitor [n (%)] 100 (20.1) 0 (0.0) 100 (29.9)
HRV
Log10 SDNN, msec 1.5 ± 0.25 1.5 ± 0.25 1.5 ± 0.25
Log10 HF, msec2 1.9 ± 0.66 1.8 ± 0.62 1.9 ± 0.68
Log10 LF, msec2 2.0 ± 0.52 2.0 ± 0.50 2.0 ± 0.54
Log10 LF:HF 0.10 ± 0.49 0.22 ± 0.47 0.04 ± 0.49
Table 2. Twenty-four–hour moving averages of outdoor air pollution and apparent temperature, and room
temperature during the HRV measurement.
Mean ± SD Range
PM2.5 (µg/m3) 11.4 ± 8.0 0.45–62.9
PN concentration (no./cm3) 28,942 ± 13,527 8,538–74,675
BC (µg/m3) 0.92 ± 0.47 0.19–2.6
O3 (ppb) 23.0 ± 13.0 2.6–84.5
NO2 (ppb) 22.7 ± 6.2 7.0–40.1
SO2 (ppb) 4.9 ± 3.4 0.95–24.7
CO (ppm) 0.50 ± 0.24 0.13–1.8
Apparent temperature (°C) 11.4 ± 9.9 –5.2–35.6
Room temperature (°C) 24.5 ± 1.4 20.0–30.0Results
Table 1 shows the demographic and clinical
characteristics and HRV measurements of the
subjects. The study participants were all male,
with average age of 72.7 years (SD = 6.6 years).
Seventy-two participants had diabetes (14.5%)
on the basis of previously mentioned criteria.
Hypertension and IHD prevalences were 67.4
and 28.6%, respectively. People with hyper-
tension were older, had higher levels of BMI
and FBG, and were more likely to have IHD,
have diabetes, and be taking hypertension
medications.
Air pollution and temperature levels are
summarized in Table 2. The median time of
ECG monitoring was 1000 hr. Levels of all
pollutants except O3 decreased after peaking
around 0700 hr. All air pollution concentra-
tions during the study period were within
the National Ambient Air Quality Standards
(U.S. EPA 2004).
Of the air pollutants examined, only
PM2.5 and O3 showed several signiﬁcant asso-
ciations with the HRV outcomes. Table 3
presents the estimated percent changes of
HRV in single- and two-pollutant models for
various lags of PM2.5 and O3. After adjusting
for potential confounders, HF decreased by
13.2% (95% CI, –1.0% to 25.4%) and
LF:HF ratio increased by 14.5% (95% CI,
2.9–27.5%) per SD (8.0 µg/m3) increase in
the 24-hr moving average of PM2.5. We saw
stronger associations with the 48-hr PM2.5: a
20.8% (95% CI, 4.6–34.2%) decrease in
HF and an 18.6% (95% CI, 4.1–35.2%)
increase in LF:HF ratio per 8.0-µg/m3
increase. We observed a reduction in LF of
11.5% (95% CI, 0.4–21.3%) associated with
1 SD (13 ppb) increment in the 4-hr O3,
which was similar in magnitude but only
marginally signiﬁcant with a 24-hr average. In
two-pollutant models, the magnitudes of
the percent changes for both PM2.5 and O3
diminished slightly.
We found no significant association of
HRV with PN, NO2, SO2, and CO for any of
the exposure averaging periods. For brevity
and comparability, Table 4 presents the HRV
associations using the averaging periods for
gaseous pollutants that showed the strongest
effect for O3 (4 hr), and the 48-hr averaging
period for PN and BC to correspond with the
strongest PM2.5 effects. An SD (0.47 µg/m3)
elevation in 48-hr BC was associated with a
13.2% (95% CI, –1.1 to 29.6%) increase in
the LF:HF ratio. The point estimates for asso-
ciations between PN and BC, and HRV meas-
ures were negative, but gaseous pollutants
(SO2 and CO) were positively related.
We also conducted stratified analyses
by IHD, hypertension, and diabetes status
(Table 5). The associations of all HRV indices
with PM2.5 and O3 were stronger in people
with IHD. People with IHD showed 2-fold
reductions of SDNN in relation to 48-hr
PM2.5 compared with people without IHD.
The interaction between 4-hr O3 and IHD
was statistically signiﬁcant for SDNN (p = 0.02
for the interaction term), HF (p = 0.01), and
LF (p = 0.004). We also observed consistently
stronger associations between all HRV indices
and PM2.5 and O3 among people with hyper-
tension. The associations observed in SDNN
and LF with PM2.5 were stronger in people
with diabetes, with almost 4-fold higher
percent changes. However, diabetes did not
modify the effect of O3 on HRV.
We assessed whether each antihyperten-
sive medication modiﬁed the effects of PM2.5
and O3 on HRV (Table 6). We found a sig-
nificant interaction between use of calcium-
channel blocker and PM2.5 for LF (p = 0.04).
Moreover, subjects who were not taking a
calcium-channel blocker showed larger reduc-
tions in SDNN and LF in relation to O3. In
particular, the association of O3 exposure
with reduced LF in the full cohort seems to
be driven by the subjects not taking calcium-
channel blockers, with a substantial (although
imprecisely estimated) increase in LF associ-
ated with O3 exposure in subjects on the
drug. As a result of this effect on LF as well as
HF, a marginally significant association was
seen between O3 and SDNN (total HRV)
as well.
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Table 3. Estimated percent changes (95% CIs) in HRV in single (PM2.5 or O3) and two-pollutant (PM2.5 and
O3) models for PM2.5 and O3 in various lagged moving averages.
Outcome, model, predictor 4-hr moving average 24-hr moving average 48-hr moving average
Log10 SDNN
Single-pollutant
PM2.5 –0.1 (–5.0 to 4.9) –2.2 (–7.7 to 3.6) –5.4 (–11.8 to 1.5)
O3 –3.6 (–8.9 to 2.0) –5.3 (–11.7 to 1.7) –2.2 (–10.0 to 6.1)
Two-pollutant
PM2.5 0.2 (–4.8 to 5.5) –0.3 (–6.6 to 6.3) –5.0 (–12.2 to 2.7)
O3 –3.6 (–9.0 to 2.1) –5.1 (–12.2 to 2.5) –0.2 (–8.8 to 9.1)
Log10 HF
Single-pollutant
PM2.5 –6.3 (–17.8 to 6.7) –13.2 (–25.4 to 1.0)* –20.8 (–34.2 to –4.6)**
O3 –9.3 (–21.8 to 5.3) –11.1 (–26.2 to 7.1) –2.6 (–21.6 to 21.1)
Two-pollutant
PM2.5 –5.1 (–17.1 to 8.6) –8.6 (–22.9 to 8.3) –20.3 (–35.2 to –2.1)**
O3 –9.4 (–22.1 to 5.4) –7.9 (–24.9 to 13.0) 6.5 (–15.9 to 34.9)
Log10 LF
Single-pollutant
PM2.5 5.7 (–4.6 to 17.1) –0.6 (–11.9 to 12.1) –6.0 (–18.9 to 8.9)
O3 –11.5 (–21.3 to –0.4)** –10.9 (–23.1 to 3.3) –6.3 (–21.1 to 11.2)
Two-pollutant
PM2.5 6.2 (–4.6 to 18.1) 3.9 (–9.2 to 18.8) –3.6 (–18.1 to 13.5)
O3 –11.3 (–21.3 to –0.1)** –12.2 (–25.3 to 3.2) –5.0 (–21.2 to 14.6)
Log10 (LF:HF)
Single-pollutant
PM2.5 12.9 (3.0 to 23.7)** 14.5 (2.9 to 27.5)** 18.6 (4.1 to 35.2)**
O3 –2.4 (–12.1 to 8.3) 0.2 (–12.1 to 14.2) –3.9 (–17.4 to 11.9)
Two-pollutant
PM2.5 11.9 (1.8 to 22.9)** 13.7 (0.9 to 28.0)** 21.0 (4.8 to 39.8)**
O3 –2.1 (–12.0 to 8.8) –4.7 (–17.4 to 9.9) –10.7 (–24.4 to 5.3)
Coefficients are expressed as percent change per 1 SD (8 µg/m3 for PM2.5 and 13 ppb for O3), adjusting for age; BMI;
MAP; FBG; cigarette smoking; use of beta-blocker, calcium-channel blocker, and/or ACE inhibitor; room temperature;
season; and cubic smoothing splines (3 df) for moving averages of apparent temperature corresponding for the predictor.
*p < 0.1. **p < 0.05.
Table 4. Estimated percent changes (95% CIs) in HRV for other pollutants.
48-hr moving average 4-hr moving average
Outcome PN BC NO2 SO2 CO
Log10 SDNN –0.7 (–9.3 to 8.9) –3.4 (–10.2 to 3.9) 1.2 (–3.1 to 5.7) 2.3 (–1.7 to 6.4) 2.0 (–2.9 to 7.3)
Log10 HF –4.1 (–24.7 to 22.1) –13.8 (–28.9 to 4.4) –0.9 (–11.7 to 11.2) 5.6 (–4.9 to 17.3) 8.8 (–4.6 to 24.1)
Log10 LF –7.0 (–23.2 to 12.6) –2.4 (–16.2 to 13.6) 1.1 (–7.7 to 10.7) 2.2 (–5.9 to 11.1) 3.2 (–7.0 to 14.6)
Log10 (LF:HF) –3.0 (–18.2 to 15.0) 13.2 (–1.1 to 29.6)* 2.0 (–5.9 to 10.6) –3.2 (–10.1 to 4.2) –5.1 (–13.5 to 4.1)
Coefﬁcients are expressed as percent change per 1 SD (13,527/cm3 for PN, 0.47 µg/m3 for BC, 6.2 ppb for NO2, 3.4 ppb for SO2, and 0.24 ppm for CO) adjusting for age; BMI; MAP; FBG;
cigarette smoking; use of beta-blocker, calcium-channel blocker, and/or ACE inhibitor; room temperature; season; and cubic smoothing splines (3 df) for moving averages of apparent
temperature corresponding for the predictor.
*p < 0.1.We found no significant interaction
between PM2.5 and O3, and use of beta-blocker
or ACE inhibitor. However, the effect of both
pollutants on LF was substantially reduced by
beta-blocker drugs. In those taking beta-block-
ers, the decrease in HF was larger than that in
LF in relation to PM2.5, compared with those
who had never taken those medications. Thus,
a larger increase in LF:HF ratio was observed in
participants who were taking beta-blocker.
However, the association with ACE inhibitors
was opposite: There was a larger increase in
LF:HF ratio associated with PM2.5 among
those not taking that medication.
Discussion
This study is consistent with previous evidence
that PM and O3 are associated with decreased
HRV, particularly for PM and HF, a para-
sympathetic (vagal) modulation of the heart.
The associations of HRV were strongest with
the 48-hr moving averages of particles, but O3
had a shorter-term impact (4 hr and 24 hr).
Furthermore, subjects with IHD and hyper-
tension appeared to have larger reductions in
HRV measures in relation to both PM2.5 and
O3 exposures. People with diabetes had larger
decreases of SDNN and LF associated with
PM2.5. In addition, we found evidence for an
association with BC, a marker of trafﬁc particles.
When we examined medications, calcium-
channel blockers had the most profound effect
on the pollution associations, particularly for
O3. This modification was primarily on LF,
suggesting that this drug is blocking effects of
pollution on the sympathetic pathway. If any-
thing, the parasympathetic response was
enhanced in these subjects. As expected, beta-
blockers seemed to reduce the LF response
of both pollutants. By contrast, use of ACE
inhibitors did not consistently or signiﬁcantly
modify pollution effects. Drug use patterns in
these subgroups are related to underlying con-
ditions, thus limiting the interpretability of
these results. Nevertheless, they suggest that
air pollution has the ability to affect both sym-
pathetic and parasympathetic pathways. The
sympathetic response seems mediated by path-
ways related to calcium ﬂux into cells, whereas
the parasympathetic response seems likely to
be due to other mechanisms.
Previous studies have consistently reported
PM associations with decreased HRV in older
adults (Creason et al. 2001; Gold et al. 2000;
Holguin et al. 2003; Liao et al. 1999, 2004;
Pope et al. 1999, 2004) (Table 7). Our results
are consistent with those. For example, esti-
mated decreases in HF resulting from an
exposure to a PM2.5 increment of 10 µg/m3 in
the previous studies were 24.1, 14.9, 19.3, and
5.1%. The last result is for a 10-µg/m3
increase in PM10 and is not directly compara-
ble. We found a 16.2% reduction. Given the
CIs (Table 7), these look fairly similar.
Three studies also evaluated the effect of
O3 on cardiac autonomic function, primarily
HF (Gold et al. 2000; Holguin et al. 2003;
Liao et al. 2004). The difference in measuring
times used in the studies preclude quantitative
comparisons of results, but there was substan-
tial variability. In the present study, O3-related
decreases in HF ranged from 2.6 to 11.1%
depending on choice of moving averages of
O3, but all estimates were insigniﬁcant.
Current knowledge about pathophysiologic
mechanisms that connect air pollution exposure
and alterations in the autonomic nervous sys-
tem is limited. One plausible mechanism is that
inhalation of PM causes oxidative stress directly
or via acute pulmonary inflammation.
Oxidative stress in the lungs seems to induce
proinﬂammatory mediators, such as cytokines
(Donaldson et al. 2001), to increase extracellu-
lar calcium inﬂux possibly through activation of
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Table 5. Estimated percent changes (95% CIs) in HRV associated with 48-hr PM2.5 and 4-hr O3 stratiﬁed by hypertension, IHD, and diabetes.
Hypertension IHD Diabetes
Outcome, predictor Without (n = 162)a With (n = 335)a Without (n = 355) With (n = 142) Without (n = 425)b With (n = 72)b
Log10 SDNN
PM2.5 –2.4 (–13.2 to 9.8) –8.1 (–15.7 to 0.3)* –3.5 (–11.1 to 4.7) –8.4 (–20.4 to 5.5) –4.7 (–11.4 to 2.6) –16.6 (–36.3 to 9.2)
O3 1.8 (–7.4 to 11.8) –5.5 (–12.1 to 1.5)* –1.0 (–7.3 to 5.8) –8.1 (–17.7 to 2.7) –5.7 (–11.1 to 0.1)* 4.0 (–17.3 to 30.6)
Log10 HF
PM2.5 –14.4 (–36.8 to 15.9) –24.5 (–40.4 to –4.5)** –18.0 (–33.7 to 1.5)* –24.1 (–48.3 to 11.4) –20.8 (–34.8 to –3.9)** –17.0 (–58.3 to 65.1)
O3 8.8 (–14.7 to 38.7) –17.0 (–31.6 to 0.7)* 1.6 (–14.4 to 20.5) –29.4 (–47.6 to –4.9)** –13.7 (–26.3 to 1.0)* 5.7 (–40.7 to 88.1)
Log10 LF
PM2.5 –2.9 (–23.5 to 23.2) –10.5 (–25.8 to 7.9) –7.0 (–21.3 to 9.9) 0.5 (–26.7 to 37.7) –5.0 (–18.6 to 10.8) –19.1 (–54.2 to 42.9)
O3 –5.4 (–21.6 to 14.1) –12.6 (–25.0 to 1.9)* –4.8 (–16.7 to 8.8) –25.8 (–41.9 to –5.3)** –13.2 (–23.4 to –1.7)** –8.4 (–41.7 to 44.1)
Log10 LF:HF
PM2.5 13.5 (–9.4 to 42.1) 18.6 (0.4 to 40.0)** 13.3 (–2.4 to 31.6) 32.5 (0.5 to 74.7)* 20.0 (4.8 to 37.5)** –2.6 (–39.4 to 56.6)
O3 –13.1 (–27.0 to 3.5) 5.3 (–8.2 to 20.8) –6.3 (–16.7 to 5.5) 5.1 (–15.9 to 31.4) 0.6 (–9.9 to 12.4) –13.3 (–41.1 to 27.6)
Coefﬁcients are expressed as percent change per 1 SD (8 µg/m3 for PM2.5 and 13 ppb for O3) adjusting for age; BMI; MAP; FBG; cigarette smoking; use of beta-blocker, calcium-channel
blocker, and/or ACE inhibitor; room temperature; season; and cubic smoothing splines (3 df) for moving averages of apparent temperature corresponding for the predictor.
aMAP and use of beta-blocker, calcium-channel blocker, and/or ACE inhibitor not included in the model. bFBG not included in the model. *p < 0.1. **p < 0.05.
Table 6. Estimated percent changes (95% CIs) in HRV associated with 48-hr PM2.5 and 4-hr O3 stratiﬁed by use of beta-blocker, calcium-channel blocker, and ACE
inhibitor.
Use of beta-blocker Use of calcium channel blocker Use of ACE inhibitor
Outcome, predictor No (n = 334)a Yes (n = 163)a No (n = 427)b Yes (n = 70)b No (n = 397)c Yes (n = 100)c
Log10 SDNN
PM2.5 –4.6 (–12.4 to 4.0) –7.5 (–18.5 to 5.1) –6.9 (–13.8 to 0.6)* 2.8 (–14.3 to 23.3) –5.1 (–12.0 to 2.4) –1.8 (–19.4 to 19.6)
O3 –5.0 (–11.2 to 1.6) –0.5 (–11.1 to 11.4) –4.9 (–10.6 to 1.3) 1.2 (–11.7 to 16.1) –2.8 (–8.7 to 3.4) –9.2 (–21.9 to 5.5)
Log10 HF
PM2.5 –17.8 (–34.2 to 2.6)* –25.4 (–47.3 to 5.7) –23.1 (–37.1 to –6.1)** –15.6 (–49.5 to 41.2) –23.5 (–37.4 to –6.5)** 8.7 (–34.2 to 79.7)
O3 –7.0 (–21.7 to 10.6) –14.8 (–37.1 to 15.5) –10.9 (–24.2 to 4.8) –9.7 (–38.4 to 32.4) –7.0 (–21.0 to 9.6) –23.7 (–48.2 to 12.4)
Log10 LF
PM2.5 –11.3 (–25.3 to 5.4) –0.5 (–25.0 to 32.0) –9.3 (–22.4 to 6.0) –0.6 (–36.5 to 55.8) –6.0 (–19.6 to 9.8) 8.8 (–29.4 to 67.7)
O3 –13.8 (–24.5 to –1.5)** –8.1 (–28.3 to 17.8) –14.4 (–24.5 to –2.9)** 11.6 (–19.8 to 55.4) –11.3 (–21.8 to 0.6)* –12.3 (–37.0 to 22.2)
Log10 LF:HF
PM2.5 8.0 (–8.2 to 27.0) 33.4 (6.5 to 67.0)** 17.9 (2.5 to 35.7)** 17.8 (–19.0 to 71.4) 22.8 (6.7 to 41.3)** 0.1 (–30.1 to 43.5)
O3 –7.3 (–18.2 to 5.0) 7.8 (–11.5 to 31.3) –3.9 (–14.2 to 7.6) 23.5 (–5.8 to 62.0) –4.7 (–15.0 to 6.8) 15.0 (–13.1 to 52.3)
Coefﬁcients are expressed as percent change per 1 SD (8 µg/m3 for PM2.5 and 13 ppb for O3) adjusting for age; BMI; MAP; FBG; cigarette smoking; use of beta-blocker, calcium-channel
blocker, and/or ACE inhibitor; room temperature; season; and cubic smoothing splines (3 df) for moving averages of apparent temperature corresponding for the predictor.
aUse of beta-blocker not included in the model. bUse of calcium-channel blocker not included in the model. cUse of ACE inhibitor not included in the model. *p < 0.1. **p < 0.05.Article | Park et al.
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calcium channels in the plasma membrane
(Stone et al. 2000), and to inactivate nitric
oxide (Thomas et al. 2001). These effects are
considered to cause an increase in sympathetic
and a reduction in vagal tone (Aronson et al.
2001; Chowdhary et al. 2002; Rodenbaugh
et al. 2003), which may be linked with cardiac
events, such as ventricular arrhythmias and
myocardial infarction. In general, we ﬁnd air
pollution associated with greater reductions in
vagal tone than in sympathetic activity.
A study from the Utah Valley (USA)
found positive associations between PM10 and
r-MSSD (Pope et al. 1999). Additionally,
dogs exposed to concentrated ambient air par-
ticles showed signiﬁcantly higher HF and LF
compared with ﬁltered air exposure (Godleski
et al. 2000). Godleski et al. (2000) argued that
too much elevation in parasympathetic stimu-
lation may deteriorate cardiac status and result
in a fatal bradyarrhythmia. A large follow-up
study in Rotterdam, the Netherlands, found
that elderly subjects in the highest quartile as
well as the lowest quartile of SDNN had sig-
niﬁcantly increased risks for cardiac mortality,
suggesting that in the elderly, alterations in
HRV in either direction might be adverse
(de Bruyne et al. 1999).
Few previous studies have evaluated modi-
fiers of the air pollution–HRV association.
Our results agree with two such studies, which
showed larger decreases in HRV among people
with hypertension (Holguin et al. 2003; Liao
et al. 2004). Although dysregulation of the
autonomic nervous system plays a role in the
pathogenesis of hypertension, the causal mech-
anism of modiﬁcation by hypertension has not
been discussed. Hypertension is associated with
lower baseline HRV and endothelial dysfunc-
tion (John and Schmieder 2003; Schroeder
et al. 2003; Singh et al. 1998). Hypertensive
people may have higher levels of oxidative-
stress–induced inﬂammatory responses. These
existing impairments may make hypertensive
people less able to accommodate the additional
oxidative stress related to air pollution exposure
and therefore could explain the enhanced effect
on HRV.
We observed a larger reduction in HRV
among people with diabetes compared with
subjects without diabetes. Diabetes is known
to be associated with low autonomic function
(Burger and Aronson 2001; Singh et al. 2000),
and has been reported to modify the associa-
tion of PM with both hospital admissions
(Zanobetti and Schwartz 2001) and deaths
(Bateson and Schwartz 2004). Several epidemi-
ologic studies showed that LF power, which
reflects mainly sympathetic modulation, was
more influenced by diabetes than any other
HRV index (Burger and Aronson 2001; Singh
et al. 2000). The present study also showed
that decreases in LF in relation to PM2.5 expo-
sure were larger in people with diabetes than
those in people without diabetes (–19.1 vs.
–5.0%). Both diabetes and PM have been
associated with oxidative-stress–induced
inﬂammation and endothelial and autonomic
dysfunctions. Therefore, susceptible individuals
who have preexisting inflammation due to
diabetes may be more responsive to airborne
particles exposure.
We found the strongest effects of PM2.5
and O3 in 48-hr and 4-hr moving averages,
respectively. The rationale for the moving
average model is that air pollution can lead to
adverse health events occurring not only on
the same day but also on several subsequent
days (Schwartz 2000). Hence, the response to
an acute pollution exposure could be distrib-
uted over a number of days. Because hourly
measured concentrations of air pollution were
available, we could evaluate several lagged
models with end times matched to each par-
ticipant’s ECG measure, an improvement
over traditional approaches using ﬁxed calen-
dar days. We found stronger particle pollu-
tant associations in longer lagged models but
stronger O3 associations in shorter ones.
A potential limitation of this study is that
we measured ECG once for each subject, so
subject-specific variation of HRV measures
may not be ruled out as a potential con-
founder. However, this variation would have
to be correlated with air pollution levels for it
to confound the observed associations. We
collected information on many possible fac-
tors that would affect autonomic function,
but the covariates included in the model may
not cover all predictors of individual varia-
tions of HRV. A longitudinal design would
provide for better adjustment of within-
subject variation in the observed associations
and allow examination of differences in base-
line autonomic function over time.
Table 7. Summary of the studies that assessed the association between ambient PM and HRV.
Population (no./mean or Ambient PM
Reference Design age range/study area) level (µg/m3) Covariates adjusted Main resultsa
Liao et al. 1999 Longitudinal 26 volunteers (3 weeks) 24-hr PM2.5, Age, sex, cardiovascular health SDNN, –8.8 (–14.9 to 0.0)
Mean, 81 years 16.1 ± 6.9 status HF, –24.1 (–42.5 to 0.0)
Baltimore LF, –22.4 (–39.7 to 0.0)
Pope et al. 1999 Longitudinal 7 (29 person days) PM10, no Barometric pressure at 1700 hr SDNN, –1.4 (–2.1 to –0.6)
Mean, 70 years concentration mountain time, HR SDANN, –1.4 (–2.4 to –0.5)
Utah Valley reported r-MSSD, 1.9 (–0.2 to 3.9)
Gold et al. 2000 Longitudinal 21 (163 observation) 4-hr PM2.5, 15.3 Uses of calcium or beta-blockers, At slow breathing:
Range, 53–87 years (Range, 2.9–48.6) ACE inhibitor SDNN, –2.9 (–7.8 to 2.1)
Boston r-MSSD, –10.6 (–18.3 to –2.9)
Creason et al. 2001 Longitudinal 56 nonsmokers (4 weeks) 24-hr PM2.5, 20.5 Age, sex, CV status, trend, maximum HF, –14.9 (–25.9 to –4.5)
Mean, 82 years (Range, 7.8–45.3) temperature, mean DPT LF, –12.9 (–20.6 to –2.3)
Baltimore
Holguin et al. 2003 Longitudinal 34 (384 observations) 24-hr PM2.5, Age, HR, hypertension HF, –19.3 (–29.2 to –7.7)
Mean, 79 years 30.4 ± 9.9 LF, –8.4 (–19.3 to 0.2)
Mexico City LF:HF, 24.2 (–7.5 to 66.7)
Pope et al. 2004 Longitudinal 88 (250 observations) 24-hr PM2.5, Interactive spline smooths for SDNN, –2.7 (–3.9 to –1.4)
Range, 54–89 years 23.7 ± 20.2 temperature, RH, HR SDANN, –1.7 (–3.3 to –0.2)
Utah r-MSSD, –6.1 (–9.2 to –3.0)
Liao et al. 2004 Cross-sectional 4,899 24-hr PM10, Age, sex, ethnicity, BMI, SDNN, –2.4 (–3.8 to –1.0)
Mean, 62 years 24.3 ± 11.5 education, smoking, CV medications, HF, –5.1 (–8.0 to –2.1)
ARIC Study CHD, diabetes, hypertension, HR, LF, –1.7 (–4.7 to 1.3)
season, temperature, RH, sky cover
Present study Cross-sectional 497 males 24-hr PM2.5, Age, MAP, smoking, FBG, use of SDNN, –2.7 (–9.5 to 4.6)
Mean, 73 years 11.4 ± 8.0 ACE inhibitor, room temperature, HF, –16.2 (–30.7 to 1.3)
Normative Aging Study apparent temperature, season LF, –0.7 (–14.6 to 15.4)
in Boston LF:HF, 18.5 (3.7 to 35.4)
Abbreviations: SDANN, standard deviation of all 5-min NN interval means; CHD, coronary heart disease; CV, cardiovascular disease; HR, heart rate; DPT, dew-point temperature; RH,
relative humidity.
aPercent change (95% CI) for an increase of 10 µg/m3 in PM2.5.Article | Air pollution and heart rate variability
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In this study, many potential confounding
factors were included in the model. BMI; blood
total cholesterol, high-density lipoprotein, and
triglyceride levels; alcohol consumption; and
respiratory and cardiovascular disease history
did not confound the association between air
pollution and HRV. We also measured the
ECG at a stable temperature and adjusted for
the temperature of the room where the ECG
was taken, as well as for ambient meteorologic
factors, including apparent temperature and
season. Therefore, the observed associations are
less likely to reﬂect bias due to the confounding
factors.
Although we did not conduct personal
exposure monitoring during the time of the
test, the monitoring site was relatively close
(1 km) to the examination site. Moreover,
evidence suggests that ambient measures of
PM have relatively uniform spatial distribu-
tion across urban areas and the longitudinal
correlation between daily changes in exposure
and daily changes in ambient concentrations
are high (Sarnat et al. 2000). Therefore, PM
concentrations at the monitoring site should
be a good surrogate of PM exposure.
This study cohort consists of all males and
almost all whites. Sex and race may be impor-
tant determinants of HRV as well as modiﬁers
of the association between air pollution and
HRV, as was observed by Liao et al. (2004).
This population-based study suggests that
short-term exposures to PM2.5 and O3 are
predictors of alterations in cardiac autonomic
function as measured by HRV among older
adults. Persons with IHD, hypertension, and
diabetes appear to be more susceptible to
autonomic dysfunction related to PM2.5
exposure. The consistency of the effect modi-
fication observed in this and other studies
strengthens evidence that these conditions
mark susceptibility to air pollution exposure
and provides new information to guide
research on underlying biologic mechanisms.
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